Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple ...

Nvidia sold its entire 7.71 million share stake in Recursion Pharmaceuticals by December 31, 2025 Recursion stock swung 14% lower intraday Wednesday before closing 2% higher ARK Invest bought 1.25 ...

OpenJDK project teams will focus work on features such as value types, code reflection, AOT compilation, and structured concurrency in the coming year. Oracle’s Java team in 2026 will work toward ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

A weekend leverage flush pushed BTC below $88,000 before a sharp rebound. Bitcoin is trading at a pivotal level that analysts say could determine whether the market holds its broader uptrend or slips ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Eleanor has an undergraduate degree in zoology from the University of Reading and a master’s in wildlife documentary production from the University of Salford. Eleanor has an undergraduate degree in ...